ARTICLE | Clinical News
Isotechnika starts psoriasis trial
October 3, 2001 7:00 AM UTC
Isotechnika (TSE:ISA) began Canadian Phase II testing of its ISATX247 small molecule immunosuppressive agent in psoriasis patients. The double-blind trials will last 12 weeks. ...